Islatravir: in vitro CHO chromosomal aberrations (mitigated by inosine); negative Ames and in vivo rat micronucleus
“While ISL induced chromosomal aberrations in an in vitro Chinese hamster ovary cell assay, this effect was mitigated by the addition of inosine, suggesting it may be related to a perturbation of nucleoside/nucleotide pools rather than direct DNA interaction. Negative results in both a bacterial reverse mutation (Ames) test and an in vivo rat micronucleus assay support this interpretation.”
✓ VerifiedFDA multi-discipline review, p. 193Source ↗
Carcinogenicity
Islatravir: 2-year rat and 26-week rasH2 mouse: not carcinogenic
“Consistent with this profile, ISL was non-carcinogenic in a 2-year study in rats and in a 26-week study in rasH2 transgenic mice.”
✓ VerifiedFDA multi-discipline review, p. 193Source ↗
Reproductive & developmental
No fertility effects in rats (~1000x); rat skeletal malformations only at ~5100x, developmental NOEL ~500x
“ISL had no effect on the fertility of male or female rats at exposures ~1000 times the human exposure at the RHD. In rats, skeletal malformations were noted only at very high exposures (~5100 times the exposure at the RHD), with a developmental no-observed-effect level (NOEL) established at exposures ~500 times the human exposure at the RHD.”
✓ VerifiedFDA multi-discipline review, p. 193Source ↗
Safety pharmacology
Transient heart rate and blood pressure increases in rats and monkeys at >1,000-fold clinical Cmax; no QTc prolongation
“While high doses produced transient increases in heart rate (HR) and blood pressure (BP) in rats and monkeys, no QTc prolongation was observed, and effects occurred only at exposures (Cmax) >1,000-fold the clinical exposure at the RHD.”
✓ VerifiedFDA multi-discipline review, p. 203Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative